A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Avacopan (Primary)
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLASSIC
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 11 Apr 2018 Accoridng to ChemoCentryx media release, safety, renal parameters and quality of life outcomes from this study are being presented during the 2018 Spring Clinical Meetings of the National Kidney Foundation (NKF).
    • 10 Jun 2017 Biomarkers information updated
    • 07 Nov 2016 Accoridng to ChemoCentryx media release, positive results will be presented at the American Society of Nephrology (ASN) Kidney Week 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top